Stock BIIB34 BIOGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Biogen Inc. Sao Paulo

Equities

BIIB34

BRBIIBBDR001

Market Closed - Sao Paulo
Other stock markets
 10:25:03 2024-04-25 EDT 		5-day change 1st Jan Change
171.4 BRL -2.16% Intraday chart for Biogen Inc. -.--% -16.49%
05-22 US Equity Markets Close Down Wednesday After Fed Minutes Raise Inflation Concerns MT
05-22 Sector Update: Health Care Stocks Slightly Higher Late Afternoon MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Biogen : “LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in South Korea
PU
BIIB Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
PR
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BU
BIIB Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
BU
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm
PR
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen
PR
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
AQ
BIIB INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
BU
Pomerantz Law Firm Announces the Filing of a Class Action Against Biogen Inc. and Certain Officers - BIIB
PR
US Equity Markets Close Down Wednesday After Fed Minutes Raise Inflation Concerns
MT
Sector Update: Health Care Stocks Slightly Higher Late Afternoon
MT
Sector Update: Health Care Stocks Advance Wednesday Afternoon
MT
Sector Update: Health Care
MT
Biogen Agrees to Buy Human Immunology Biosciences For up to $1.8 Billion
MT
Top Midday Stories: US Targets August 1 Start Date for China Tariff Hikes; CFPB Says BNPL Requires Credit Card-Level Oversight; Target Shares Fall on Earnings Miss; Third BHP Bid Rejected by Anglo American
MT
Wedbush Raises Biogen Price Target to $219 From $215, Maintains Neutral Rating
MT
Biogen: agreement to acquire HI-Bio
CF
Biogen to Acquire Human Immunology Biosciences for up to $1.8 Billion
MT
Biogen to buy Human Immunology Biosciences in up to $1.8 billion deal
RE
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIIB Stock
  4. BIIB34 Stock
  5. News Biogen Inc.